Filing Details
- Accession Number:
- 0001209191-22-006792
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-02-03 16:26:09
- Reporting Period:
- 2022-02-01
- Accepted Time:
- 2022-02-03 16:26:09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1829069 | Bastiano Sanna | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp, Cell & Genetic Therapies | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-02-01 | 11,628 | $0.00 | 44,204 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2022-02-01 | 12,314 | $0.00 | 56,518 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2022-02-01 | 526 | $243.64 | 55,992 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2022-02-02 | 670 | $250.04 | 55,322 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-02-02 | 141 | $251.47 | 55,181 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-02-02 | 149 | $253.07 | 55,032 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-02-02 | 64 | $253.95 | 54,968 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-02-02 | 16 | $254.54 | 54,952 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | A | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022.
- Restricted stock unit award that vests in installments beginning on 02/24/2023.
- Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $250.04 (range $250.00 to $250.97).
- Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $251.47 (range $251.09 to $251.85).
- Open market sales reported on this line occurred at a weighted average price of $253.07 (range $252.44 to $253.42).
- Open market sales reported on this line occurred at a weighted average price of $253.95 (range $253.47 to $254.42).
- Open market sales reported on this line occurred at a weighted average price of $254.54 (range $254.47 to $254.80).
Billionaire Hedge Funds
